Major biopharmaceutical companies, including Novo Nordisk, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Eccogene, AstraZeneca, and others, are driving innovation in the GLP-1 agonists space through robust pipelines, strategic collaborations, and the development of next-generation treatments targeting diabetes, obesity, and related metabolic disorders
Diabetes and Metabolism 7 (1), e462
These injections can enhance the overall health and appearance of your skin by promoting cell turnover, increasing collagen production, and improving skin tone and texture
In glucocorticoid-treated rats mimicking osteoporosis, Ipamorelin counteracted steroid-induced bone loss by enhancing bone formation without changing bone mineral density markers